Compare IMAX & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | ENOV |
|---|---|---|
| Founded | 1967 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Fluid Controls |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1997 | 2008 |
| Metric | IMAX | ENOV |
|---|---|---|
| Price | $40.68 | $24.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $44.44 | ★ $48.75 |
| AVG Volume (30 Days) | 987.0K | ★ 1.0M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $410,212,000.00 | N/A |
| Revenue This Year | $9.80 | $6.49 |
| Revenue Next Year | $7.11 | $5.56 |
| P/E Ratio | $64.39 | ★ N/A |
| Revenue Growth | ★ 16.47 | N/A |
| 52 Week Low | $20.48 | $21.00 |
| 52 Week High | $43.16 | $40.70 |
| Indicator | IMAX | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 53.70 |
| Support Level | $35.94 | $21.30 |
| Resistance Level | $43.16 | $26.41 |
| Average True Range (ATR) | 1.68 | 1.20 |
| MACD | 0.27 | 0.33 |
| Stochastic Oscillator | 66.11 | 60.17 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.